JPMorgan Chase & Co. Purchases 25,494 Shares of BioLife Solutions Inc (NASDAQ:BLFS)

JPMorgan Chase & Co. grew its position in shares of BioLife Solutions Inc (NASDAQ:BLFS) by 144.1% in the 1st quarter, Holdings Channel reports. The firm owned 43,185 shares of the medical equipment provider’s stock after acquiring an additional 25,494 shares during the quarter. JPMorgan Chase & Co.’s holdings in BioLife Solutions were worth $410,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. FMR LLC bought a new stake in shares of BioLife Solutions in the 1st quarter valued at $2,684,000. Victory Capital Management Inc. increased its stake in shares of BioLife Solutions by 77.1% in the 4th quarter. Victory Capital Management Inc. now owns 7,669 shares of the medical equipment provider’s stock valued at $106,000 after acquiring an additional 3,338 shares in the last quarter. State Street Corp increased its stake in shares of BioLife Solutions by 5.4% in the 4th quarter. State Street Corp now owns 137,211 shares of the medical equipment provider’s stock valued at $2,220,000 after acquiring an additional 7,001 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of BioLife Solutions by 8.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 18,398 shares of the medical equipment provider’s stock valued at $298,000 after acquiring an additional 1,402 shares in the last quarter. Finally, Bank of Montreal Can increased its stake in shares of BioLife Solutions by 1,607.5% in the 4th quarter. Bank of Montreal Can now owns 48,373 shares of the medical equipment provider’s stock valued at $783,000 after acquiring an additional 45,540 shares in the last quarter. Hedge funds and other institutional investors own 59.70% of the company’s stock.

BLFS opened at $16.35 on Wednesday. The company has a market capitalization of $400.56 million, a price-to-earnings ratio of 39.88 and a beta of 1.53. The firm’s fifty day moving average price is $15.98 and its two-hundred day moving average price is $14.01. BioLife Solutions Inc has a 1 year low of $7.37 and a 1 year high of $21.18.

Several analysts have recently weighed in on BLFS shares. Oppenheimer reiterated a “buy” rating on shares of BioLife Solutions in a research note on Wednesday, May 6th. B. Riley reduced their price target on shares of BioLife Solutions from $24.00 to $22.00 and set a “buy” rating for the company in a research report on Monday, May 4th. TheStreet downgraded shares of BioLife Solutions from a “b-” rating to a “c” rating in a research report on Thursday, March 12th. Zacks Investment Research raised shares of BioLife Solutions from a “hold” rating to a “buy” rating and set a $18.00 price target for the company in a research report on Tuesday, May 19th. Finally, Maxim Group reissued a “buy” rating and issued a $18.00 price target on shares of BioLife Solutions in a research report on Saturday, May 16th. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $21.33.

In related news, VP Aby J. Mathew sold 10,000 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $13.40, for a total value of $134,000.00. Following the transaction, the vice president now directly owns 223,157 shares of the company’s stock, valued at approximately $2,990,303.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael Rice sold 18,750 shares of the business’s stock in a transaction dated Friday, June 19th. The stock was sold at an average price of $16.37, for a total transaction of $306,937.50. Following the completion of the transaction, the chief executive officer now directly owns 232,973 shares in the company, valued at $3,813,768.01. The disclosure for this sale can be found here. Insiders have sold a total of 635,826 shares of company stock worth $9,279,036 over the last ninety days. Insiders own 22.30% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Featured Story: What is the outlook for the FAANG stocks?

Want to see what other hedge funds are holding BLFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioLife Solutions Inc (NASDAQ:BLFS).

Institutional Ownership by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.